biotech / news / / MarketScreener
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd.
The Phase 3 OptiTROP-Lung04 trial showed sac-TMT doubled median PFS versus chemotherapy in EGFR-TKI-resistant NSCLC.
KEY POINTS
- Sacituzumab tirumotecan (sac-TMT) achieved statistically significant improvements in both PFS and OS in this trial.
- Sac-TMT uses a novel linker and a belotecan-derived payload with a drug-to-antibody ratio of 7.4.
- Sac-TMT is the first TROP2 ADC drug approved globally for lung cancer treatment.
COMPANIES
Summarized by Newsio from MarketScreener. How we summarize →